A Case of Lung Cancer Exhibiting Pleoymorphic Carcinoma Transformation Resistance Following Treatment With Osimertinib That Was Successfully Treated Using Local Ablative Treatment DOI Creative Commons
Yoshiaki Nagai, Hiromitsu Ohta,

Hikari Amari

et al.

Thoracic Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 25, 2024

ABSTRACT Various studies have reported resistance mechanisms and treatment methods after epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor treatment; however, policies not yet been established, few cases transformation to pleomorphic carcinoma (PC) as the mechanism. Herein, we report case of a 66‐year‐old woman who was diagnosed with Stage 4A lung adenocarcinoma (cT2bN0M1b) through bronchoscopic biopsy. Genetic profiling revealed an EGFR L858R mutation; therefore, osimertinib administered first‐line therapy achieved partial response. After 46 months treatment, metastases remained under control; primary tumor enlarged therefore resected. Pathological examination confirmed diagnosis PC. testing surgical pathology specimen showed that mutation retained, patient considered drug‐resistant owing histologic The continued had no recurrence at 9 postoperatively. Transformation PC following administration is rare, this unique case. This study approved by Jichi Medical University Saitama Center Ethics Committee (S24‐073), written informed consent obtained from patient.

Language: Английский

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice DOI Open Access
Hollis Viray,

Andrew J. Piper‐Vallillo,

Page Widick

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(6), P. 1079 - 1079

Published: March 7, 2024

Osimertinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that used for first-line therapy in EGFR mutated non-small cell lung cancer (NSCLC) based on results randomized FLAURA trial (ClinicalTrials.gov number NCT02296125). We performed retrospective analysis baseline characteristics and clinical outcomes 56 real-world patients treated with osimertinib. In total, 45% were determined to be FLAURA-eligible 55% FLAURA-ineligible published inclusion/exclusion criteria aforementioned trial. For outcomes, median osimertinib time treatment discontinuation (TTD) all was 16.9 months (95% CI: 12.6–35.1), whereas TTD 31.1 14.9–not reached) cohort 12.2 8.1–34.6 months) cohort. Re-biopsy at acquired resistance disclosed both on- off-target mechanisms. The most common therapies following included local followed by post-progression osimertinib, platinum-doublet chemotherapy or without combinatory targeted therapies. overall survival 32.0 15.7–not reached), not reached cohort, it 16.5 Our data support use real-word settings highlight need designing registration trials are more inclusive patient/disease seen routine practice. It yet if evolving combination strategies (either plus amivantamab lazertinib) will similarly translate from settings.

Language: Английский

Citations

4
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings DOI Open Access
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(14), P. 2589 - 2589

Published: July 19, 2024

Platinum-based chemotherapy is the current standard treatment option in patients with

Language: Английский

Citations

4
Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors DOI Open Access
Ching‐Yi Lee, Shih‐Wei Lee, Yi‐Chiung Hsu

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2042 - 2042

Published: Feb. 26, 2025

The development of tyrosine kinase inhibitors (TKIs) for late-stage epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) represented a drastic change in the treatment cancer. Drug resistance develops after certain period first-line TKI treatment, which has led to decades changing guidelines EGFR-mutant NSCLC. This study discussed potential mechanisms drug against and successive strategies. Next-generation sequencing (NGS) may play role evaluation treatment. Emerging combination regimens ongoing trials were discussed. Potential future strategies management proposed this study.

Language: Английский

Citations

0
Treatment Approaches for Oligoprogressive Non-Small Cell Lung Cancer: A Review of Ablative Radiotherapy DOI Open Access

William Gombrich,

Nicholas Eustace, Yufei Liu

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1233 - 1233

Published: April 5, 2025

Oligoprogressive disease refers to the setting of a prior or ongoing receipt systemic therapy, with typically up three metastatic areas having increased in size and/or avidity compared start therapy. The role local ablative therapy (LAT) including radiation has mostly been evaluated oligometastatic limited data oligoprogression. A similar principle using may be applied consolidative for oligoprogressive disease. If can control majority disease, and few therapy-resistant clones continue proliferate, then potentially controlling those resistant while maintaining beneficial. Doing so also extend duration benefit reserve next line options at later point, improve progression free survival (PFS). Here, we review current evaluating non-small cell lung cancer (NSCLC) trials.

Language: Английский

Citations

0
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis DOI
Jonathan N. Priantti, Yu Fujiwara, Francisco Cézar Aquino de Moraes

et al.

JCO Precision Oncology, Journal Year: 2024, Volume and Issue: 8

Published: Nov. 1, 2024

PURPOSE The activity of osimertinib is not fully characterized in non–small-cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor ( EGFR ) mutations. Therefore, we conducted a systematic review and meta-analysis to assess the safety efficacy patients NSCLC harboring somatic METHODS PubMed, Embase, Cochrane Library were searched for eligible studies reporting mutations defined as any other than exon 19 deletion, L858R T790M mutations, 20 insertion, except when compound. Then, performed pool survival outcomes antitumoral activity, including intracranial (ic) response adverse events. RESULTS Fifteen comprising 594 included. most frequently observed solitary G719X 25% (81/327) L861Q 21% (69/327). common compound 12% (23/192) S768I 11% (22/192). Pooled analysis showed an objective rate (ORR) 51.30% (95% CI, 45.80 56.81), disease control (DCR) 90.11% 86.27 92.96), median progression-free 9.71 months 7.96 11.86), overall 16.79 9.93 28.39). icORR was 45.96% 30.18 62.17), icDCR 95.76% 69.84 100). Osimertinib well tolerated frequency grade 3 or more events 21.77% 6.24 43.33). CONCLUSION demonstrated robust without unanticipated concerns.

Language: Английский

Citations

3
Brief Report: Osimertinib Plus Capmatinib for Patients with MET-Altered EGFR-Mutant NSCLC following progression on front line therapy DOI
Omar Elghawy, Adam Barsouk,

Lauren Reed-Guy

et al.

Clinical Lung Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

1
A Case of Lung Cancer Exhibiting Pleoymorphic Carcinoma Transformation Resistance Following Treatment With Osimertinib That Was Successfully Treated Using Local Ablative Treatment DOI Creative Commons
Yoshiaki Nagai, Hiromitsu Ohta,

Hikari Amari

et al.

Thoracic Cancer, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 25, 2024

ABSTRACT Various studies have reported resistance mechanisms and treatment methods after epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor treatment; however, policies not yet been established, few cases transformation to pleomorphic carcinoma (PC) as the mechanism. Herein, we report case of a 66‐year‐old woman who was diagnosed with Stage 4A lung adenocarcinoma (cT2bN0M1b) through bronchoscopic biopsy. Genetic profiling revealed an EGFR L858R mutation; therefore, osimertinib administered first‐line therapy achieved partial response. After 46 months treatment, metastases remained under control; primary tumor enlarged therefore resected. Pathological examination confirmed diagnosis PC. testing surgical pathology specimen showed that mutation retained, patient considered drug‐resistant owing histologic The continued had no recurrence at 9 postoperatively. Transformation PC following administration is rare, this unique case. This study approved by Jichi Medical University Saitama Center Ethics Committee (S24‐073), written informed consent obtained from patient.

Language: Английский

Citations

1